RT Journal Article
SR Electronic
T1 Response of the Lambert‐Eaton myasthenic syndrome to treatment of associated small‐cell lung carcinoma
JF Neurology
JO Neurology
FD Lippincott Williams & Wilkins
SP 1552
OP 1552
DO 10.1212/WNL.40.10.1552
VO 40
IS 10
A1 Chalk, C. H.
A1 Murray, N.M.F.
A1 Newsom-Davis, J.
A1 O'Neill, J. H.
A1 Spiro, S. G.
YR 1990
UL http://n.neurology.org/content/40/10/1552.abstract
AB We evaluated the outcome in 16 patients with Lambed-Eaton myasthenic syndrome (LEMS) associated with histologically verified small-cell carcinoma (SCC). Thirteen patients received specific tumor therapy (chemotherapy, radiation therapy, or resection) and most also received pharmacologic and immunologic treatment for LEMS. Seven of 11 patients surviving for more than 2 months after tumor therapy showed substantial neurologic improvement (1 patient being in complete remission at 7 years); in 3 of 11 improvement was transient. An EMG index of disease severity (compound muscle action potential amplitude in abductor digiti minimi) was significantly increased at final follow-up (p < 0.01; n = 11). A pretreatment amplitude >3.0 m V was a good prognostic sign. We conclude that a combined treatment approach in SCC-LEMS usually results in neurologic improvement.